title: Management of rifamycins-everolimus drug-drug interactions in a liver-transplant patient with pulmonary tuberculosis.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Lefeuvre
authors.forename: Stanislas
authors.initials: S
authors.lastname: Rebaudet
authors.forename: Eliane M
authors.initials: EM
authors.lastname: Billaud
authors.forename: Benjamin
authors.initials: B
authors.lastname: Wyplosz
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000601:surgery*; D051544:Cytochrome P-450 CYP3A / Q000096:biosynthesis; D004347:Drug Interactions; D004790:Enzyme Induction / Q000187:drug effects; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008113:Liver Neoplasms / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D017828:Rifabutin / Q000627:therapeutic use*; D012293:Rifampin / Q000009:adverse effects*; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D017828:Rifabutin; D000068338:Everolimus; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D012293:Rifampin; D020123:Sirolimus